For generations, the treatment of psychological suffering has leaned heavily on medication alone — a partial answer to a deeply human question. In Utah, a clinic called Sovegna, founded by psychiatrist Dr. Susie Wiet, is attempting something more complete: pairing the emerging practice of Ketamine Assisted Psychotherapy with sustained therapeutic work, and surrounding it with a broader integrative wellness program. It is part of a quiet but growing reckoning in mental health care — one that asks not just how to quiet symptoms, but how to restore a whole person.
ABC 4
· Sep 27, 2022
· health
· 1 min read
Medium
Sourcing: Characterized
Ketamine-Assisted Psychotherapy Gains Traction as Mental Wellness Treatment
◉
Health & Medicine
8098 related articles
Moderna's personalized mRNA melanoma vaccine shows promise in preventi…
CBS News · 100% match
Blood test could predict Covid-19 mortality risk, study finds
BreakingNews.ie · 99% match
Hadassah performs world's first alpha radiation treatment for recurren…
jpost.com · 99% match
Dr. Reddy's Wins Semaglutide Approval as Novo Nordisk Patent Challenge…
NDTV Profit · 99% match
EU safety committee reviews reports of menstrual changes after mRNA CO…
CNBC · 99% match
Related Coverage
The Guardian · Aug 20
Hundreds of thousands await GCSE results as gender gap narrows to 10-year low
Hundreds of thousands of UK students received GCSE results showing overall grade improvements in 2025, with the gender g…
The Straits Times · Aug 20 Ebola spreads beyond Congo epicentre, overwhelming treatment capacityEbola cases in DRC are accelerating outside the initial Ituri epicenter, with North Kivu and Haut-Uélé provinces experie…
Science Daily · Aug 20 1,000+ genetic switches explain why women face higher autoimmune disease riskResearchers identified over 1,000 genetic switches that function differently in male and female immune cells, explaining…
News-Medical · Aug 20 Brain's Local Wiring May Buffer Cognitive Decline in Older AdultsUSC researchers found that white matter integrity helps protect cognitive function in older adults by compensating for g…
Bias & Framing
⚖
Article presents ketamine-assisted psychotherapy as innovative mental health solution with minimal critical examination or balanced perspective on risks and efficacy.
Bias Direction
center-right
Confidence
HIGH
Promotional framing disguised as health journalism. Uses testimonial-style narrative focused on clinic's credentials and treatment benefits without investigative scrutiny. Frames ketamine therapy as 'cutting-edge' and 'comprehensive' without comparative analysis.
well-documented fact
cutting-edge treatments
tremendous relief
better, more comprehensive solution
potent prescription medications
long-term recovery
Medical skeptics or researchers questioning ketamine therapy efficacy
Potential risks, side effects, or contraindications of ketamine treatment
Cost-benefit analysis compared to traditional psychiatric treatments
Regulatory status and FDA approval details for this specific application
Patient testimonials expressing concerns or negative outcomes
Independent clinical trial data or peer-reviewed research citations
Perspectives from mental health professionals not affiliated with the clinic
Geopolitical Impact
🌎
This article is a local wellness advertisement for a Utah mental health clinic offering ketamine-assisted psychotherapy; it has no geopolitical implications.
Escalation Risk
low
Confidence
HIGH
Economic Lens
📈
Ketamine-assisted psychotherapy clinics are expanding mental health treatment offerings, representing emerging market opportunity in alternative psychiatric care with potential to reduce reliance on traditional prescription medications.
Market Signal
bullish
Confidence
MED
Healthcare/Mental Health Services
Pharmaceutical/Alternative Medicine
Wellness and Behavioral Health
Medical Clinics and Outpatient Services
Consumers gain access to alternative mental health treatments potentially offering faster relief from depression, anxiety, and trauma with fewer side effects than traditional medications. However, treatment costs may not be fully covered by insurance, creating affordability barriers for lower-income households.
Regulatory bodies may need to establish clearer guidelines for ketamine-assisted therapy protocols, insurance coverage standards, and practitioner licensing requirements. FDA oversight of ketamine use in psychiatric settings may increase as demand grows. Potential for expanded insurance reimbursement if clinical efficacy is further validated.